ABSTRACT
Ritanserin or R 55 667 (Figure 18.1) has been described to be a potent serotonin–5HT2 antagonist, different from classical serotonin antagonists in that it selectively binds to serotonin–5HT2 but not to serotonin–5HT1 receptor sites (Leysen et al., 1985). Ritanserin is also a pure LSD antagonist in contrast to other serotonin antagonists such as cyproheptadine, metergoline and methysergide which act as mixed agonist/antagonists in the LSD–saline discrimination procedure (Colpaert et al., 1982). Clinically, ritanserin was found to improve the quality of sleep (Idzikowski et al., 1986) and to possess mood elevating properties (Reyntjens et al., 1986; Hoppenbrouwers et al., 1986). Chemical and tridimensional structure of ritanserin. https://s3-euw1-ap-pe-df-pch-content-public-p.s3.eu-west-1.amazonaws.com/9780203771310/de7f7c77-1f7a-4494-ac64-d661f0ba6601/content/fig18_1_B.tif" xmlns:xlink="https://www.w3.org/1999/xlink"/>
